|
|
|
|
|
|
by Duller-Finite
2128 days ago
|
|
|
This is an interesting and well-done paper. It is, however, difficult to evaluate these mouse studies because, unlike human ACE2, mouse ACE2 doesn't facilitate SARS-CoV-2 cell entry. Therefore, they had to first deliver hACE2 either with an intranasal adenovirus injection, or use transgenic mice expressing hACE2 in a pattern that does not recapitulate its expression in humans. It does seem like they do an especially good job at blocking infections in the respiratory system, but that's both the system that they primed for infection and where they provided the ChAd vaccine, so I don't know how fair of a comparison the intramuscular injection experiments are. |
|
|